Finally, we used a panel of three cellular models recently derived from patients with lung cancer, which included MGH134 from a patient with EGFR mutant NSCLC who developed resistance to first line erlotinib therapy via a EGFRT790M resistance mutation, MGH1109 from a treatment naïve patient with EGFR mutant NSCLC, and MGH006 from a treatment naïve patient with EML4-ALK variant 1 mutant NSCLC. This evidence concerns the gene ALK and lung carcinoma.